Search Results

Precision BioSciences, Inc. today announced its addition to the Russell Microcap® Index.

Precision BioSciences, Inc. today announced that members of management will participate in the following upcoming investor conferences in June.

Precision BioSciences, Inc. (Nasdaq: DTIL) today announced that it will publish financial results for the first quarter 2024 and provide a business update on Monday, May 13, 2024.

Precision BioSciences, Inc. today announced that, on May 13, 2024, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees.

Precision BioSciences, Inc. (Nasdaq: DTIL) today announced that it had granted Caribou Biosciences, Inc., a leading CRISPR genome-editing cell therapy company, a non-exclusive, worldwide license, with the right to sublicense, to one of Precision’s foundational cell therapy patent families for use with CRISPR in the field of human therapeutics.